Biotron Ltd has released a press release.
Commencement Phase 2 Covid-19 Clinical Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Biotron
- Completion of Phase 2 HIV-1 Clinical Trials
- International Presentation of BIT225 COVID-19 Data
- $1.43M R&D rebate received
- Commencement of Rights Trading - BITRC
- Renounceable Issue
Later from Biotron
- Second Site Approved for Phase 2 Covid-19 Trial
- Completion of phase 2 covid clinical trial
- Response to ASX Price Query
- Positive outcomes in BIT225 phase 2 clinical trial in hiv
- BIT225 Phase 2 HIV Efficacy Trial Meets Primary Objectives
Follow Biotron into a list and get an email when it puts out news.
Follow Biotron